Emerging Role of Dual Glucagon-Like Peptide-1 (GLP-1)/Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Cardiovascular Prevention
Dual hormone agonists show cardiovascular benefits beyond weight loss, broadening their potential clinical applications.
This Cureus review examines the emerging cardiovascular prevention role of dual GLP-1/GIP receptor agonists like tirzepatide, covering mechanism of action and clinical evidence. It highlights their potential beyond metabolic indications.
What the study was
- Study design
- Narrative review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cureus
Why it surfaced
Relevant to cardiometabolic watchlist. Cureus review, limited novelty over existing literature.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.